<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808950</url>
  </required_header>
  <id_info>
    <org_study_id>SP848-nBCC-1104</org_study_id>
    <nct_id>NCT01808950</nct_id>
  </id_info>
  <brief_title>Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)</brief_title>
  <official_title>Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is the observation and description of the preliminary efficacy of
      resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Histological cure rate</measure>
    <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global judgment of efficacy (by investigator) by means of a 7-point scale</measure>
    <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of local tolerability by means of 5-point scales</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>local skin reactions as erythema, edema, erosion/ulceration, exudate, dryness, encrustation judged by investigator by means of 5-point scales (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of systemic tolerability based on haematology and blood chemistry values and vital signs</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global judgment of tolerability by investigator by means of a 6-point scale</measure>
    <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Nodular Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - A</intervention_name>
    <arm_group_label>0.06% Resiquimod Gel - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - B</intervention_name>
    <arm_group_label>0.06% Resiquimod Gel - B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - C</intervention_name>
    <arm_group_label>0.06% Resiquimod Gel - C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent form.

          -  Male or non-pregnant, non-lactating female, ≥ 18 years.

          -  Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk
             or arms.

          -  nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth.

          -  Willing and able to participate in the trial as an outpatient and comply with all
             trial requirements.

        Exclusion Criteria:

          -  nBCC located close to or at mouth or eyes.

          -  Patients who have had an organ transplant.

          -  Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV),
             known thyroid abnormalities, known depression.

          -  An open wound or an infection in treatment area.

          -  Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the
             treatment or surrounding area that might impair trial assessments.

          -  Evidence of an active infection or systemic cancer.

          -  Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle
             pain, chills) within a week before start of the trial.

          -  Known allergy or hypersensitivity to any of the trial gel ingredients.

          -  Evidence of unstable or uncontrolled clinically significant medical conditions as
             determined by the investigator (e.g., renal or hepatic disease).

          -  Current alcohol abuse or chemical dependency as assessed by the investigator.

          -  Patient who is detained or committed to an institution by a law court or by legal
             authorities.

          -  Participation in another clinical trial within one month before start of the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hauttumorcentrum Charité (HTCC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>March 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
